Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

1L Therapy in CLL: What Are the Best Options?

SOHO Brazil 2024

J. Burger

Clinical Practice Updates in CLL/SLL

Integrity CE

M. Cortese, D. Wallace, A. Niu

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

ASCO® 2023 Summary: "Experts Discuss Key Abstracts in CLL"

Insights from 2023 ASCO® Annual Meeting

S. O'Brien, C. Coombs

3L in CLL: The Best Options in a Patient Double-Refractory to Covale…

SOHO Brazil 2024

J. Burger

Frontline CLL Learnings From Phase 3 RESONATE-2, iLLUMINATE, and E19…

Cleveland Clinic Taussig Cancer Institute

A. Winter

CLL Treatment Sequencing: The Importance of First Choice

City of Hope

S. Rosen

Choosing BTKi or BCL2i or Combination Therapy for 1L CLL

Danielle Brander

Practice-Changing Updates in Indolent B-Cell Lymphomas

Massachusetts General Hospital Cancer Center

J. Soumerai

Sequencing Therapies in CLL: The Importance of First-Line Treatment …

Nicole Lamanna

Fixed-Duration Treatment in CLL: Current Considerations

UCI Health

E. Brem

Experts Discuss Highlights and Key Takeaways in CLL From ASCO® and E…

2024 ASCO® Annual Meeting Insights Hub

K. Rogers, J. Woyach

Single vs. Multiple Agents in 2L Therapy for CLL

SOHO Brazil 2024

J. Burger

Therapeutic Options in CLL in 2023: Choosing the Initial Therapy Wis…

Indy Hematology Review

J. Woyach

Venetoclax vs. BTKis in CLL Treatment

City of Hope

A. Danilov

State-of-the-Art in CLL Treatment

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

A. Cuneo

Impact of Ibrutinib Dose Modifications in CLL

Ruemu Birhiray

Efficacy of Ibrutinib Arms Across ALPINE and ELEVATE-RR Trials in R/…

Insights from 2023 ASH Annual Meeting

M. Shadman

Debates in CLL: Continuous or Finite Duration Therapy

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Jain